Clinical Trial: A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease

U.S., Aug. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07113262) titled 'A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease' on July 28.

Brief Summary: A multicenter clinical study to evaluate the efficacy and safety of IBI311 in subjects with inactive thyroid eye disease. The study consists of two parts, with a maximum duration of approximately 64 weeks.

Study Start Date: Aug. 15

Study Type: INTERVENTIONAL

Condition: Thyroid Eye Disease

Intervention: DRUG: IBI311

Teprotumumab N01 injection (code name IBI311)

DRUG: Placebo

Placebo

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Disclaimer: Curated by...